Baboon syndrome induced by cetuximab

Archives of Dermatology

Volumn 144, Issue 2, 2008, Pages 272-274

  Sans, Veronique ^b   Jouary, Thomas ^a   Hubiche, Thomas ^b   Smith, Denis ^b   Milpied, Brigitte ^b   Taieb, Alain ^b  

^a HÔPITAL SAINT ANDRÉ   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ATENOLOL; CETUXIMAB; CLOBETASOL; FLUOROURACIL; FOLINIC ACID; IRBESARTAN; IRINOTECAN; NIFEDIPINE; PIRETANIDE; PRAVASTATIN; PREDNISONE;

AGED; ANAMNESIS; BABOON SYNDROME; CASE REPORT; COLON CANCER; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; HUMAN TISSUE; LETTER; LIVER METASTASIS; MALE; PRIORITY JOURNAL; PUSTULE; RASH;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AXILLA; BUTTOCKS; EXANTHEMA; HUMANS; MALE; NECK; PERINEUM;

EID: 39649113854     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archdermatol.2007.57     Document Type: Letter

References (10)

1. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317-326.
2. Mascia F, Mariani V, Girolomoni G, et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol. 2003;163(1):303-312.
3. Agero AL, Dusza W, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55(4):657-670.
4. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23(22):5235-5246.
5. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425-1433.
6. Erbitux (cetuximab) [package insert]. New York, NY: ImClone Systems Inc; March 2006.
7. Sánchez-Morillas L, Reano Martos M, Rodriguez Mosquera M, et al. Baboon syndrome. Allergol Immunopathol (Madr). 2004;32(1):43-45.
8. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51(5-6):297-310.
9. Lerch M, Bircher AJ. Systemically induced allergic exanthema from mercury. Contact Dermatitis. 2004;50(6):349-353.
10. Barbaud A. Tests cutanés dans l'investigation des toxidermies: de la physiopathologie aux résultats des investigations. Therapie. 2002;57(3):258-262.